세계의 동반진단 시장 규모 조사 및 예측 : 기술별, 적응증별, 최종사용자별, 지역별 분석(2022-2029년)

Global Companion Diagnostics Market is valued at approximately USD 6.80 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 11.0% over the forecast period 2022-2029. A companion diagnostic is a test used to ensure the usage of a comparable biological product or medication is both safe and effective. These tests are typically used to diagnose cancer. In this, an appropriate medicine is recommended based on the identified biomarker. Based on a particular patient's response, these tests offer personalized treatment. The Companion Diagnostics market is expanding because of factors such as the increasing incidence of Cancer and rising Regulatory Approvals of New Tests for Different Indications.

The rising prevalence of cancer globally is fostering market growth, according to statistics published by the World Health Organization (WHO) in February 2022, approximately 400,000 children develop cancer worldwide every year. Also, according to the statistics published by the World Cancer Research Fund International, in 2020, there were 18,094,716 million cases of cancer diagnosed globally. The International Agency for Research on Cancer estimated increase in the worldwide burden of cancer is to 27.5 million new cases by 2040. The usage of these tests is increasing due to the increased incidence of cancer worldwide, which is boosting the market's expansion. Also, it is anticipated that regulatory approvals of these tests for various indications will expand the market. For instance, in August 2022, the U.S. FDA approved Thermo Fisher Scientific Inc.'s Oncomine Dx Target Test as a companion diagnostic (CDx). This test identifies non-small cell lung cancer tumours that exhibit HER2 (ERBB2) activating mutations (SNVs & Exon 20 Insertion). In addition, the co-development of drug and diagnostic technology and favorable government support is creating lucrative growth in the market. However, the high cost of drug development and associated clinical trials may halt market growth.

The key regions considered for the Global Companion Diagnostics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the rising drug discovery activities, rising prevalence of diseases and rising regulatory approvals in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising disease prevalence, an increase in the number of collaborations for drug development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:

• Abbott Laboratories
• Agilent Technologies Inc.
• F.Hoffmann-La Roche Ltd
• Biomerieux SA
• Qiagen NV
• Siemens Healthcare Gmbh
• Thermo Fisher Scientific Inc.
• Danaher Corporation (Beckman Coulter Inc.)
• Almac Group
• Illumina Inc.

Recent Developments in the Market:

• In January 2022, Amoy Diagnostics Co. Ltd., and PREMIA Holdings (HK) Limited introduced the AmoyDx Pan Lung Cancer PCR Panel (the "PLC Panel") in Japan as a reimbursed companion diagnostic for various anti-cancer drugs.
• In January 2021,In partnership with OmniSeq Corporation, Laboratory Corporation of America Holdings unveiled OmniSeq INSIGHTsm, a complete tissue-based test for genomic and immunological profiling that makes use of next-generation sequencing (NGS) technology. By advancing precision oncology, the test hopes to enhance patient outcomes..

Global Companion Diagnostics Market Report Scope:

• Historical Data 2019-2020-2021
• Base Year for Estimation 2021
• Forecast period 2022-2029
• Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered Technology, Indication, End User Region
• Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
• Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Technology offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Technology:

• Immunohistochemistry (IHC)
• Polymerase Chain Reaction (PCR)
• In-situ Hybridization (ISH)
• Real-time PCR (RT-PCR)
• Gene Sequencing
• Other Technologies

By Indication:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Leukemia
• Melanoma
• Other Indications

By End User:

• Pharmaceutical & Biopharmaceutical Companies
• Reference Laboratories
• CROs
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Rest of the World

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
  • 1.2.1. Companion Diagnostics Market, by Region, 2019-2029 (USD Billion)
  • 1.2.2. Companion Diagnostics Market, by Technology, 2019-2029 (USD Billion)
  • 1.2.3. Companion Diagnostics Market, by Indication, 2019-2029 (USD Billion)
  • 1.2.4. Companion Diagnostics Market, by End User, 2019-2029 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Companion Diagnostics Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Companion Diagnostics Market Dynamics

• 3.1. Companion Diagnostics Market Impact Analysis (2019-2029)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing incidence of Cancer
    • 3.1.1.2. Rising Regulatory Approvals of New Tests for Different Indications
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Drug Development and Associated Clinical Trials
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Co-development of Drug and Diagnostic Technology
    • 3.1.3.2. Favourable government support

Chapter 4. Global Companion Diagnostics Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. Industry Experts Prospective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1. Assessment of the overall impact of COVID-19 on the industry
• 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Companion Diagnostics Market, by Technology

• 6.1. Market Snapshot
• 6.2. Global Companion Diagnostics Market by Technology, Performance - Potential Analysis
• 6.3. Global Companion Diagnostics Market Estimates & Forecasts by Technology 2019-2029 (USD Billion)
• 6.4. Companion Diagnostics Market, Sub Segment Analysis
  • 6.4.1. Immunohistochemistry (IHC)
  • 6.4.2. Polymerase Chain Reaction (PCR)
  • 6.4.3. In-situ Hybridization (ISH)
  • 6.4.4. Real-time PCR (RT-PCR)
  • 6.4.5. Gene Sequencing
  • 6.4.6. Other Technologies

Chapter 7. Global Companion Diagnostics Market, by Indication

• 7.1. Market Snapshot
• 7.2. Global Companion Diagnostics Market by Indication, Performance - Potential Analysis
• 7.3. Global Companion Diagnostics Market Estimates & Forecasts by Indication 2019-2029 (USD Billion)
• 7.4. Companion Diagnostics Market, Sub Segment Analysis
  • 7.4.1. Lung Cancer
  • 7.4.2. Breast Cancer
  • 7.4.3. Colorectal Cancer
  • 7.4.4. Leukemia
  • 7.4.5. Melanoma
  • 7.4.6. Other Indications

Chapter 8. Global Companion Diagnostics Market, by End User

• 8.1. Market Snapshot
• 8.2. Global Companion Diagnostics Market by End User, Performance - Potential Analysis
• 8.3. Global Companion Diagnostics Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
• 8.4. Companion Diagnostics Market, Sub Segment Analysis
  • 8.4.1. Pharmaceutical & Biopharmaceutical Companies
  • 8.4.2. Reference Laboratories
  • 8.4.3. CROs
  • 8.4.4. Others

Chapter 9. Global Companion Diagnostics Market, Regional Analysis

• 9.1. Companion Diagnostics Market, Regional Market Snapshot
• 9.2. North America Companion Diagnostics Market
  • 9.2.1. U.S. Companion Diagnostics Market
    • 9.2.1.1. Technology breakdown estimates & forecasts, 2019-2029
    • 9.2.1.2. Indication breakdown estimates & forecasts, 2019-2029
    • 9.2.1.3. End User breakdown estimates & forecasts, 2019-2029
  • 9.2.2. Canada Companion Diagnostics Market
• 9.3. Europe Companion Diagnostics Market Snapshot
  • 9.3.1. U.K. Companion Diagnostics Market
  • 9.3.2. Germany Companion Diagnostics Market
  • 9.3.3. France Companion Diagnostics Market
  • 9.3.4. Spain Companion Diagnostics Market
  • 9.3.5. Italy Companion Diagnostics Market
  • 9.3.6. Rest of Europe Companion Diagnostics Market
• 9.4. Asia-Pacific Companion Diagnostics Market Snapshot
  • 9.4.1. China Companion Diagnostics Market
  • 9.4.2. India Companion Diagnostics Market
  • 9.4.3. Japan Companion Diagnostics Market
  • 9.4.4. Australia Companion Diagnostics Market
  • 9.4.5. South Korea Companion Diagnostics Market
  • 9.4.6. Rest of Asia Pacific Companion Diagnostics Market
• 9.5. Latin America Companion Diagnostics Market Snapshot
  • 9.5.1. Brazil Companion Diagnostics Market
  • 9.5.2. Mexico Companion Diagnostics Market
  • 9.5.3. Rest of Latin America Companion Diagnostics Market
• 9.6. Rest of The World Companion Diagnostics Market

Chapter 10. Competitive Intelligence

• 10.1. Top Market Strategies
• 10.2. Company Profiles
  • 10.2.1. Abbott Laboratories
    • 10.2.1.1. Key Information
    • 10.2.1.2. Overview
    • 10.2.1.3. Financial (Subject to Data Availability)
    • 10.2.1.4. Product Summary
    • 10.2.1.5. Recent Developments
  • 10.2.2. Agilent Technologies Inc.
  • 10.2.3. F.Hoffmann-La Roche Ltd
  • 10.2.4. Biomerieux SA
  • 10.2.5. Qiagen NV
  • 10.2.6. Siemens Healthcare Gmbh
  • 10.2.7. Thermo Fisher Scientific Inc.
  • 10.2.8. Danaher Corporation (Beckman Coulter Inc.)
  • 10.2.9. Almac Group
  • 10.2.10. Illumina Inc.

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes
• 11.3. Research Assumption